EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna Therapeutics to Advance Sleep Apnea Nasal Spray

OSA is the most common sleep-related breathing disorder, affecting an estimated 1 billion people globally. Left untreated, OSA is linked to serious health risks including hypertension, cardiovascular disease, stroke, depression and excessive daytime sleepiness – contributing to workplace and car accidents. Despite OSA's prevalence, treatment has largely focused on mechanical solutions that are often uncomfortable and disruptive.  OSA is the most common sleep-related breathing disorder,...

OSA is the most common sleep-related breathing disorder, affecting an estimated 1 billion people globally. Left untreated, OSA is linked to serious health risks including hypertension, cardiovascular disease, stroke, depression and excessive daytime sleepiness – contributing to workplace and car accidents. Despite OSA's prevalence, treatment has largely focused on mechanical solutions that are often uncomfortable and disruptive. 

Mosanna is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at nighttime that helps restore the body's natural airway reflex. MOS118 targets the upper airway muscles that are responsible for maintaining airway patency. Research has shown that in OSA patients, the natural airway reflex becomes less active at night, leading to a loss of airway patency and the occurrence of apnea. The new funding will support the advancement of MOS118 through Phase 2 development while also supporting the expansion of Mosanna's pipeline. 

Mosanna also appointed veteran biotech leader David Weber, Ph.D., as President and Chief Executive Officer to guide Mosanna's next stage of growth. With more than 30 years of experience spanning drug development, capital formation and corporate strategy, Dr. Weber has led teams across both public and private life sciences companies. Dr. Weber was also appointed to Mosanna's Board of Directors. 

"Mosanna is taking a truly transformational approach to sleep apnea treatment – offering a non-invasive, non-mechanical solution designed to seamlessly fit into daily life," said Dr. Weber. "No one has sleep apnea while awake, because our bodies instinctively keep the airway open. Mosanna simply helps to restore this natural reflex during sleep – delivering a nasal spray alternative to invasive mechanical workarounds. With this funding, we're accelerating development to bring this groundbreaking treatment to patients who desperately need better options." 

Contact
EQT Press Office, [email protected] 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/eqt-life-sciences-leads-usd-80-million-series-a-funding-round-in-mosanna-therapeutics-to-advance-sle,c4160762

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/eqt-life-sciences-leads-usd-80-million-series-a-funding-round-in-mosanna-therapeutics-to-advance-sleep-apnea-nasal-spray-302476550.html